676 results match your criteria Prostate Cancer - Cryotherapy


Cryotherapy shows no inferiority compared with radical Prostatectomy for low-risk and intermediate-risk localized Prostate Cancer: a real-world study from the SEER database.

J Cancer 2020 29;11(19):5738-5745. Epub 2020 Jul 29.

Department of Urology, Institute of Urology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu 610041, China.

For localized prostate cancer (PCa) with a low disease burden, whole-gland resection seems like overtreatment, while focal therapy, including cryosurgery, can achieve similar outcomes. We aimed at comparing the long-term survival outcomes of cryotherapy and radical prostatectomy (RP) and further exploring whether RP can be replaced by cryosurgery for those with low-risk PCa. We conducted analyses from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015) and performed propensity score matching and used an instrumental variate to reduce the influence of bias and unmeasured confounders to the greatest extent. Read More

View Article and Full-Text PDF

Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.

Prostate Cancer Prostatic Dis 2021 03 19;24(1):186-192. Epub 2020 Aug 19.

Departments of Urology and Oncology, Western University, London, ON, Canada.

Background: In men with recurrence of prostate cancer post radiation therapy, further treatment remains a challenge. The default salvage option of androgen-deprivation therapy (ADT) has adverse effects. Alternatively, selected men may be offered salvage therapy to the prostate. Read More

View Article and Full-Text PDF

Mobile cancer prevention and early detection outreach in Uganda: Partnering with communities toward bridging the cancer health disparities through "asset-based community development model".

Cancer Med 2020 10 18;9(19):7317-7329. Epub 2020 Aug 18.

Uganda Cancer Institute, Kampala, Uganda.

Background: Communities in low-income countries are characterized by limited access to cancer prevention and early detection services, even for the commonest types of cancer. Limited resources for cancer control are one of the contributors to cancer health disparities. We explored the feasibility and benefit of conducting outreaches in partnership with local communities using the "asset-based community development (ABCD)" model. Read More

View Article and Full-Text PDF
October 2020

Whole-gland ablation therapy versus active surveillance for low-risk prostate cancer: a prospective study.

Cent European J Urol 2020 8;73(2):127-133. Epub 2020 Apr 8.

Department of Urology, Institut Mutualiste Montsouris, Paris, France.

Introduction: The objective of this study is assess the outcomes of whole-gland ablation (high-intensity focused ultrasound (HIFU), cryotherapy and brachytherapy) and active surveillance (AS) in patients with low-risk prostate cancer (PCa).

Material And Methods: This prospective non-randomised study included 155 patients with low-risk PCa managed with either ablative therapy or AS. Follow-up included mpMRI, biopsies, prostate-specific antigen (PSA), quality of life and complications for up to 24 months. Read More

View Article and Full-Text PDF

Minimally invasive strategies for the treatment of prostate cancer recurrence after radiation therapy: a systematic review.

Minerva Urol Nefrol 2020 Oct 4;72(5):563-578. Epub 2020 Aug 4.

Department of Urology, Campus Bio-Medico University, Rome, Italy.

Introduction: The aim of this review was to conduct a comprehensive analysis of the role of minimally invasive salvage modalities in radio-recurrent prostate cancer and the associated clinical outcomes and toxicity profiles.

Evidence Acquisition: A systematic review of the current literature was conducted through the Medline and NCBI PubMed, Scopus databases in January 2020. All papers published after 2000, concerning studies conducted on humans for radio-recurrent prostate cancer were considered for the review. Read More

View Article and Full-Text PDF
October 2020

The Impact of Performing a 3D Mapping Biopsy Prior to Primary Cryotherapy for the Treatment of Prostate Cancer.

Urology 2020 Oct 23;144:171-176. Epub 2020 Jul 23.

University of Colorado Anschutz Medical Campus, Division of Urology, Aurora, CO.

Objective: To study the implications of adding a 3D mapping biopsy (3DMB) prior to prostate cryotherapy (PCT) for the treatment of prostate cancer on the following outcomes: recurrence and biochemical failure (BCF), quality of life outcomes, and complication rates.

Methods: A retrospective analysis of patients treated with either targeted focal therapy, or subtotal CT for localized prostate cancer was performed. The cohort was stratified by patients who had only had a transrectal ultrasound-guided biopsy (TRUS) and those who had undergone 1 additional 3DMB before definitive treatment. Read More

View Article and Full-Text PDF
October 2020

A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer.

Transl Androl Urol 2020 Jun;9(3):1535-1545

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.

Although radiotherapy to the prostate for cancer is effective, recurrence occurs in 10-15% within 5 years. Traditional salvage treatments for men with radiorecurrent prostate cancer comprise of watchful waiting (WW) with or without androgen deprivation therapy (ADT) or radical prostatectomy (RP). Neither strategy provides ideal therapeutic ratios. Read More

View Article and Full-Text PDF

Focal therapy, time to join the multi-disciplinary team discussion?

Transl Androl Urol 2020 Jun;9(3):1526-1534

Department of Urology, Southampton General Hospital, University Hospital Southampton NHS Trust, Southampton, UK.

Organ preserving management is common place in renal cancer, breast cancer and many other solid organ tumours. Current strategies in managing intermediate risk prostate cancer include either whole gland treatment, in the form of radical radiotherapy or radical prostatectomy, or active surveillance. The former is associated with significant post-treatment functional morbidity, whilst the latter associated with the burden of surveillance activity and patient anxiety. Read More

View Article and Full-Text PDF

Targeting the cancer lesion, not the whole prostate.

Transl Androl Urol 2020 Jun;9(3):1518-1525

Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Modern cancer treatment aims to conserve as much healthy tissue as possible. This has been challenging in the treatment of prostate cancer due to the difficulty in imaging the gland and concerns over leaving multifocal cancer untreated. With improvements in imaging and understanding of multifocal prostate cancer evidence now shows accurate treatment of just the primary focus of cancer or the index lesion can control progression or recurrence of the disease. Read More

View Article and Full-Text PDF

Focal HIFU therapy for anterior compared to posterior prostate cancer lesions.

World J Urol 2021 Apr 7;39(4):1115-1119. Epub 2020 Jul 7.

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Fulham Palace Road, London, W6 8RF, UK.

Objective: To compare cancer control in anterior compared to posterior prostate cancer lesions treated with a focal HIFU therapy approach.

Materials And Methods: In a prospectively maintained national database, 598 patients underwent focal HIFU (Sonablate500) (March/2007-November/2016). Follow-up occurred with 3-monthly clinic visits and PSA testing in the first year with PSA, every 6-12 months with mpMRI with biopsy for MRI-suspicion of recurrence. Read More

View Article and Full-Text PDF

Oncological outcomes of salvage cryotherapy after primary radiation therapy vs. primary cryotherapy: 10-year experience at a large Canadian referral center.

Can Urol Assoc J 2020 Nov;14(11):E604-E606

Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Introduction: Salvage cryotherapy is a guideline-recommended treatment of localized prostate cancer recurrence after radiation therapy. There is little published evidence analyzing the outcomes of salvage cryotherapy for recurrent prostate cancer following different primary therapy energy modalities.

Methods: We performed a retrospective analysis of patients who received whole gland salvage cryotherapy from 2007-2017 at a large tertiary referral center after either primary radiation therapy (RT) or primary whole gland cryotherapy. Read More

View Article and Full-Text PDF
November 2020

Oncological control following partial gland ablation for intermediate-risk prostate cancer.

Urol Oncol 2020 08 31;38(8):671-677. Epub 2020 May 31.

Department of Urology, NYU Langone Health, New York, NY.

Historically, the primary objection to partial gland ablation (PGA) for management of prostate cancer (CaP) has been disease multifocality and inability to localize significant disease. Improved disease localization and risk stratification with multiparametric magnetic resonance imaging and targeted biopsy, along with its minimal adverse impact on quality of life has enabled PGA to gain acceptance. Today, the primary barrier for adopting PGA is its unknown oncological outcomes. Read More

View Article and Full-Text PDF

Techniques and Outcomes of Salvage Robot-Assisted Radical Prostatectomy (sRARP).

Eur Urol 2020 12 24;78(6):885-892. Epub 2020 May 24.

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

Background: Salvage Robot-Assisted Radical Prostatectomy (sRARP) has been described as feasible treatment for the management of localised prostate cancer (PCa) recurrence after primary treatment. However, no large reports have published cancer and quality outcomes.

Objective: To report perioperative, functional and oncologic outcomes of sRARP in patients with localised PCa recurrence. Read More

View Article and Full-Text PDF
December 2020

Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis.

Cureus 2020 May 6;12(5):e7983. Epub 2020 May 6.

Canadian Clincial Trials Group, Queen's University, Kingston, CAN.

Background Optimal management of isolated local recurrence of prostate cancer after primary radiotherapy remains to be defined. Up-front androgen deprivation therapy (ADT) is widely used but may adversely affect the quality of life and is essentially a palliative treatment. Local salvage carries a different side-effect profile and is potentially curative, but it has not been compared to ADT. Read More

View Article and Full-Text PDF

Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.

Contemp Clin Trials 2020 06 14;93:105999. Epub 2020 Apr 14.

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Introduction: Focal therapy (FT) targets individual areas of cancer within the prostate, providing oncological control with minimal side-effects. Early evidence demonstrates encouraging short-medium-term outcomes. With no randomized controlled trials (RCT) comparing FT to radical therapies, Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (CHRONOS) will compare the cancer control of these two strategies. Read More

View Article and Full-Text PDF

Influence of sociodemographic factors on treatment's choice for localized prostate cancer in Portugal.

Arch Ital Urol Androl 2020 Apr 6;92(1):45-49. Epub 2020 Apr 6.

Urology Department, Instituto Português de Oncologia Francisco Gentil, Coimbra.

Introduction: Patients with localized prostate cancer (PCa) are active participants in the choice of treatment.

Objectives: To access the effects of social and demographic factors in the choice of treatment in cases of localized PCa, in a Portuguese population.

Methods: Identification of all patients with the diagnosis of localized PCa in the last four years in an oncological centre. Read More

View Article and Full-Text PDF

An Exploratory Study of Dose Escalation Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer.

J Endourol 2020 06 5;34(6):641-646. Epub 2020 May 5.

Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.

Analysis of treatment success regarding oncological recurrence rate between standard and dose escalation focal high-intensity focused ultrasound (HIFU) of prostate cancer. In this analysis of our prospectively maintained HIFU (Sonablate 500) database, 598 patients were identified who underwent a focal HIFU (Sonablate 500) between March 2007 and November 2016. Follow-up occurred with 3-monthly clinic visits and prostate specific antigen (PSA) testing in the first year. Read More

View Article and Full-Text PDF

Re: Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.

J Urol 2020 07 6;204(1):157. Epub 2020 Mar 6.

Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.

View Article and Full-Text PDF

Management of erectile dysfunction and LUTS/incontinence: the two most common, long-term side effects of prostate cancer treatment.

Can J Urol 2020 02;27(27 Suppl 1):17-24

Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.

The two major long-term concerns associated with different options for the management of prostate cancer, (including surgery, radiotherapy, brachytherapy, cryotherapy, HIFU, etc.) include difficulties with lower urinary tract symptoms (LUTS) and/or erectile dysfunction. LUTS can be in the form of stress urinary incontinence (SUI), urge urinary incontinence (UUI), frequency/urgency, and/or voiding difficulties. Read More

View Article and Full-Text PDF
February 2020

Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Prostate Cancer Prostatic Dis 2020 09 19;23(3):537-538. Epub 2020 Feb 19.

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, Charing Cross Hospital, London, W6 8RF, UK.

View Article and Full-Text PDF
September 2020

Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Prostate Cancer Prostatic Dis 2020 06 12;23(2):232-243. Epub 2020 Feb 12.

Royal Surrey NHS Foundation Trust, Guildford, Surrey, GU2 7XX, UK.

Background: Prostate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment. Read More

View Article and Full-Text PDF

Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes.

Actas Urol Esp (Engl Ed) 2020 Apr 5;44(3):172-178. Epub 2020 Feb 5.

Departamento de Urología, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, España.

Introduction: To compare oncological, functional and post-operative outcomes of hemi (HC) vs. whole gland (WGC) cryoablation as first line treatment of localized prostate cancer.

Material And Method: Sixty-six consecutive patients undertaking whole-gland cryoablation (WGC=40) or hemi-cryoablation (HC=26) in a tertiary referral centre between 2010 and 2018 were included. Read More

View Article and Full-Text PDF

Prostate Multiparametric Magnetic Resonance Imaging Features Following Partial Gland Cryoablation.

Urology 2020 Apr 15;138:98-105. Epub 2020 Jan 15.

Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY. Electronic address:

Objective: To assess the qualitative and quantitative changes on prostate multiparametric magnetic resonance imaging (mpMRI) following partial gland ablation (PGA) with cryotherapy and correlate with histopathology.

Methods: We used 3D Slicer to generate prostate models and segment ipsilateral (treated) and contralateral peripheral and transition zones in 10 men who underwent MRI/transrectal ultrasound fusion-guided PGA during 2017-2018. Pre- and post-PGA volumes of prostate segments were compared. Read More

View Article and Full-Text PDF

Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer.

Clin Genitourin Cancer 2020 06 5;18(3):e260-e265. Epub 2019 Dec 5.

Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address:

Background: We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer.

Materials And Methods: We queried the Cryo On-Line Database registry for men who had undergone SFC and STC of the prostate for RT-persistent or recurrent disease. Propensity score weighting was used to match age at treatment, presalvage therapy prostate-specific antigen level, Gleason sum, and presalvage cryotherapy androgen deprivation therapy status. Read More

View Article and Full-Text PDF

Salvage radical prostatectomy following focal therapy: functional and oncological outcomes.

BJU Int 2020 04 9;125(4):525-530. Epub 2020 Jan 9.

Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, ON, Canada.

Objectives: To report the oncological and functional outcomes of salvage radical prostatectomy (sRP) after focal therapy (FT).

Patients And Methods: A retrospective review of all patients who underwent sRP after FT was performed. Clinical and pathological outcomes focussed on surgical complications, oncological, and functional outcomes. Read More

View Article and Full-Text PDF

Interventional therapy in malignant conditions of the prostate.

Radiologe 2019 Dec;59(Suppl 1):28-39

Klinik für Strahlentherapie, MediClin Robert Janker Klinik, Bonn, Germany.

Interventional therapies are emerging modalities for the treatment of localized prostate cancer. Their aim is to reduce the morbidity associated with radical therapies (rT) by minimizing damage to non-cancerous tissue, with priority given to sparing key structures such as the neurovascular bundles, external sphincter, bladder neck, and rectum, while maintaining local cancer control. Interventional ablative technologies deliver energy in different ways to destroy cancer cells. Read More

View Article and Full-Text PDF
December 2019

Phase I study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol.

Contemp Clin Trials Commun 2019 Dec 12;16:100471. Epub 2019 Oct 12.

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Background: Whole-gland therapy for prostate cancer, which might cause more harm than no therapy (observation or active surveillance), might be a overtreatment. In order to avoid overtreatment as well as undertreatment of localize prostate cancer, novel strategy of organ-preserving therapies have been developed to achieve both cancer control and functional preservation. For the therapeutic techniques, microwave ablation would be an option for lesion-targeted focal therapy to eradicate biopsy-proven cancer lesion with its safety margin. Read More

View Article and Full-Text PDF
December 2019

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Prostate Cancer Prostatic Dis 2020 03 14;23(1):184-193. Epub 2019 Oct 14.

Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Background: Monotherapy with immune checkpoint inhibitors has generally been unsuccessful in men with advanced prostate cancer. Preclinical data support the notion that cryotherapy may improve immune-mediated and anti-tumor responses. The objective of this study was to assess the safety and feasibility of whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation in men with oligometastatic hormone-sensitive prostate cancer. Read More

View Article and Full-Text PDF

The Scottish prostate cryotherapy service-the role of the clinical nurse specialist.

Br J Nurs 2019 Oct;28(18):S12-S16

Professor, CRUK Beatson Institute for Cancer Research, Glasgow/Institute of Cancer Sciences, University of Glasgow.

This article outlines the role of the clinical nurse specialist in establishing a Scotland-wide national designated service for prostate cryotherapy for patients with radiation-recurrent prostate cancer. The service was established in 2009 and provides prostate cryotherapy across Scotland. This article reviews and discusses the challenges involved in setting up a new service for tertiary treatment as well as highlighting the key achievements of the service. Read More

View Article and Full-Text PDF
October 2019

Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer.

Eur Urol Focus 2021 Mar 5;7(2):301-308. Epub 2019 Oct 5.

Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Background: The oncological outcomes in men with clinically significant prostate cancer following focal cryotherapy are promising, although functional outcomes are under-reported.

Objective: To determine the impact of focal cryotherapy on urinary and sexual function, specifically assessing return to baseline function.

Design, Setting, And Participants: Between October 2013 and November 2016, 58 of 122 men who underwent focal cryotherapy for predominantly anterior clinically significant localised prostate cancer within a prospective registry returned patient-reported outcome measure questionnaires, which included International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-15) questionnaires. Read More

View Article and Full-Text PDF